A Phase IIa Study of Z-207 in Patients with Seasonal Allegic Rhinitis - Investigation of the Efficacy and Safety of Z-207 after Single Injection -

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221241

Enrollment

Registered

2010-09-14

Start date

2010-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal Allergic Rhinitis

Interventions

investigational material(s) Generic name etc : Z-207 INN of investigational material : Therapeutic category code : 449 Other antiallergic agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with history of moderate to sever seasonal allergic rhinitis for at least 2 years Patient with positive reaction for Radio Allergen Sorbent Test using Japanease ceder pollen Patient exhibit both a total nasal symptom score of at least 4, and a nasal obstruction score of at least 2 under exposure to allergen using pollen challenge chamber ( Total nasal symptom score is the sum of sneezing, nasal discharge, nasal obstruction which has been scored on a scale from 0 to 4 )

Exclusion criteria

Exclusion criteria: Patient with positive reaction for Radio Allergen Sorbent Test for house dust mite Patient with positive reaction for Radio Allergen Sorbent Test for orchard grass pollen Patient who never received medical drug therapy for allergic rhinitis

Design outcomes

Primary

Measure	Time frame
Total nasal symptom score under exposure to allergen using pollen challenge chamber, and nasal symptom score natural exposure to allergen during the pollen season	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026